Organization
Bristol-Myers Squibb Company
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Bristol-Myers Squibb Company
... Access Impact: Rheumatoid Arthritis (EU5). The report covers major therapies from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Napp/Mundipharma, Roche, and UCB. Handy graphs ...
... the runaway market leader? Comparing 10 major RCC treatments from Amgen, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Novartis, Pfizer, and Roche, this report reveals: - How ...
... drive the market for pharmacy-based anticoagulation clinics. C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and ...
... onslaught of immono-oncology drugs, particularly given recent results of a combo of Bristol-Myers Squibb’s I-O drugs Opdivo with Yervoy against Sutent. RELATED: Bristol-Myers' Opdivo-Yervoy cocktail ...
... Key players include Novartis International AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Eli Lilly, Seattle Genetics, Inc., ...
... MBChB, Ph.D., as president of research and development. Dr. Burgess joins from Bristol-Myers Squibb, where he was senior vice president of development across multiple therapeutic ...
... Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D. Burgess, who had been ...
... policies being adopted. Representatives from the leading pharmaceutical companies such as Amgen, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc, Novartis AG, Eli Lilly, Merck and ...
... research organization, today announced that it has expanded its ongoing collaboration with Bristol-Myers Squibb. The next phase of the partnership will see the addition of ...
... Merck Serono. She also had a nearly 15-year successful career at Bristol-Myers Squibb (BMS), attaining the role of Senior Vice President and Head of Global ...
... two would make “more sense” than a Pfizer buy of I-O hotshot Bristol-Myers Squibb that’s been rumored for months. RELATED: Does Pfizer really want Bristol-Myers? ...
... of unprecedented challenges. The companies include financial services firm HSBC, pharmaceutical company Bristol-Myers Squibb, medical device company Boston Scientific, technology firm Nokia, paper and biofuel ...
... Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release real-world data (RWD) ...
... Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results for Opdivo (nivolumab) plus BMS-986205, a ...
... Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has ...
... Bristol-Myers Squibb has posted interim data on its IDO1 inhibitor in combination with ...
... the study in the first quarter of 2018 and will work with Bristol-Myers Squibb to present data from the study at a future medical meeting. ...
... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline ...
... a head start in this setting with recent approvals for Keytruda; however, BMS, AstraZeneca, Roche and Merck Group/Pfizer still have much to play for. As ...
... report has been added to Research and Markets' offering. Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic ...
... Street’s 80.1% forecast. RELATED: AstraZeneca's Mystic shortfall is an immuno-oncology shake-up for Bristol-Myers and a bolster for Merck and Roche And the analyst focus on ...
... 1Q 2018 - TG4010 + nivolumab (Opdivo(R)): * Nivolumab is provided by Bristol-Myers Squibb, within a collaborative agreement with UC Davis Medical Center (USA) * ...
... deals. The largest deal during this period was the $1,250m agreement between Bristol-Myers Squibb and Promedior, pursuant to which Bristol-Myers Squibb was granted an exclusive ...
... Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Jefferies London Healthcare Conference on ...
... in Previously Untreated Advanced or Metastatic RCC. In July, Exelixis and Bristol-Myers Squibb (BMS) announced the initiation of CheckMate 9ER, the pivotal phase 3 trial ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤